Table 1:
Clinical characteristics of the patients
| Group 1 (n=20) | Group 2 (n=22) | Group 3 (n=25) | p value | |
|---|---|---|---|---|
| Age (year) | 53.3 ± 9,9 | 48.7 ± 10.7 | 49.2 ± 8.6 | 0.212 |
| BMI (kg/m2) | 25.2 ± 4,5 | 26.2 ± 3.4 | 26.7 ± 2.5 | 0.258 |
| Hypertensive state | 0.004 | |||
| Normal | 7 (35%) | 7 (31.8 %) | 4 (16%) | |
| Pre-hypertension | 5 (25%) | 5 (22.7%) | 18 (72%) | |
| Stage 1 hypertension | 8 (40%) | 10 (45.4%) | 3 (12%) | |
| Antihypertensive | 0,029 | |||
| Yes | 8 (40%) | 10 (45.4%) | 3 (12%) | |
| No | 12 (60%) | 12 (64.6%) | 22 (88%) | |
| CKD | ||||
| Stage 3 | 6 (30%) | 8 (36.3%) | 0 | |
| Stage 4 | 3 (15%) | 4 (18.2%) | 0 | |
| Stage 5 | 11 (55%) | 10 (45.4%) | 0 | |
| Erectile function status | ||||
| No ED | 0 | 22 (10: Stage 5 CKD) (4: Stage 4 CKD) (8: Stage 3 CKD) |
25 | |
| Mild ED | 0 | 0 | 0 | |
| Mild to moderate ED | 2 (2: Stage 5 CKD) | 0 | 0 | |
| Moderate ED | 4 (3: Stage 5 CKD) (1: Stage 4 CKD) |
0 | 0 | |
| Severe ED | 14 (6: Stage 5 CKD) (2: Stage 4 CKD) (6: Stage 3 CKD) |
0 | 0 | |
| Hemoglobin levels | 11.9 ± 1.8a | 12.7 ± 1.7b | 13.8 ± 1.2 | <0.001 |
| ADMA levels | 0.6 ± 0.1a | 0.6 ± 0.1b | 0.4 ± 0.1 | <0.001 |
| Total testosterone | 2.7 ± 1,1a | 3.6 ± 1.2a | 5.7 ± 1.9 | <0.001 |
| Prolactin levels | 16.9 ± 2.2a | 14.6 ± 1,7a,c | 11.3 ± 2.2 | <0.001 |
compared with group 1
ADMA: asymmetrical dimethylarginine; BMI: body mass index; CKD: chronic kidney disease; ED: erectile dysfunction; IIEF-EFD: erectile function domain of International Index of Erectile Function questionnaire.